Der Fettsäurestoffwechsel unterliegt vielfältigen Kontrollmechanismen. So wird der Fettsäureabbau über die Induktion und Aktivität spezifischer Enzyme reguliert. Ein zentraler Regulator ist dabei der nukleäre Rezeptor Peroxisomenproliferator-aktivierter-Rezeptor-α (PPARα). PPARα wird durch freie Fettsäuren in der Zelle aktiviert und fördert über die Induktion von Zielgenen den Fettsäuretransport und -abbau sowie die Gluconeogenese und Ketogenese. Der Anstieg an freien Fettsäuren beim Fasten, aber auch im Diabetes aktiviert PPARα. Unabhängig davon wurde in beiden Stoffwechsellagen auch eine erhöhte Expression des nukleären Rezeptors Constitutiver-Androstan-Rezeptor (CAR) und einiger CAR-Zielgene, vorrangig Enzyme des Fremdstoffmetabolismus wie Cytochrom P450 2B (CYP2B), festgestellt. Bei der Adaption an eine Fastensituation scheinen PPARα- und CAR-Signalwege über einen bisher unbekannten Mechanismus miteinander verschaltet zu sein. In der vorliegenden Arbeit sollte der der Verschaltung zugrunde liegende Mechanismus anhand eines Modelsystems, der PPARα-Agonisten-vermittelten Verstärkung der Phenobarbital (PB)-abhängigen Induktion des CAR-Zielgens CYP2B, in vitro untersucht werden. Zudem sollte die physiologische Relevanz einer durch PPARα-Agonisten vermittelten Modulierung der CYP2B-Aktivität in einer Ganztierstudie in vivo belegt werden. Die verwendeten synthetischen PPARα-Agonisten steigerten in primären Hepatozyten der Ratte signifikant die Phenobarbital (PB)-abhängige mRNA- und Protein-Expression sowie die Aktivität von CYP2B. Ohne vorherige PB-Behandlung induzierten PPARα-Agonisten CYP2B nicht. In Gegenwart von PB war die Steigerung der CYP2B-Aktivität durch PPARα-Agonisten dosisabhängig. In einem Luciferase-Reportergenassay wurde gezeigt, dass die Induktion durch PB unter der Kontrolle des CYP2B1-Promotors von einem distalen PBREM (PB-responsive-enhancer-module), an welches CAR binden kann, abhängig war. PPARα-Agonisten steigerten diese PB- und PBREM-abhängige Reportergentranskription und induzierten die CAR-mRNA und CAR-Proteinexpression. Sie aktivierten die Transkription eines Reportergens unter der Kontrolle eines Promotorfragments von bis zu 4,4 kb oberhalb des mutmaßlichen CAR-Transkriptionsstarts. Mit Hilfe von Deletionskonstrukten konnte ein potentielles Peroxisomenproliferator-aktivierter-Rezeptor-responsives Element (PPRE) im CAR-Promotorbereich von -942 bp bis -930 bp identifiziert werden, welches essentiell für die Initiation der Transkription durch PPARα-Agonisten ist. In band shift Experimenten akkumulierte verstärkt Kernprotein mit diesem PPRE. Ein Überschuss an unmarkiertem Wildtyp-CAR-Reportergenvektor, nicht aber an CAR-Reportergenvektor mit PPRE-Deletion, konnte mit dem markierten PPRE um die Bindung von Kernprotein konkurrieren. Nach Chromatin-Immunpräzipitation mit einem PPARα-Antikörper wiederum wurde das betreffende PPRE amplifiziert. Bei in vivo Experimenten an männlichen Ratten resultierte die Behandlung mit PPARα-Agonisten in einer signifikanten Induktion der CAR-mRNA-Expression und signifikant erhöhter PB-abhängiger CYP2B-Aktivität. Die physiologisch Relevanz wurde durch weiterführenden Experimente unterstrichen, in denen gezeigt wurde, dass die Fasten-abhängige Induktion von CAR in PPARα-defizienten Mäusen unterdrückt war. Diese Experimente legen nahe, dass durch PPARα-Agonisten aktiviertes PPARα an das PPRE im CAR-Promotorbereich von -942 bp bis -930 bp bindet und dadurch die CAR-Transkription induziert. Somit kann CAR als PPARα-Zielgen betrachtet werden, was die Schlussfolgerung zulässt, dass die PPARα- und CAR-Signalwege über die direkte Bindung von PPARα an den CAR-Promotor unmittelbar miteinander verknüpft sind. Allerdings ist davon unabhängig eine Aktivierung von CAR, etwa durch PB, für die vermehrte Induktion von CAR-Zielgenen notwendig . Die physiologische Relevanz der PPARα-abhängige CAR-Expression zeigt sich in den Ganztierexperimenten, bei denen die Wirksamkeit der PPARα-Agonisten bestätigt werden konnte. CAR-abhängig induzierte Enzyme sind nicht nur in großem Umfang am Fremdstoffmetabolismus beteiligt, sondern auch am Abbau von Schilddrüsenhormonen und Glucocorticoiden. Sie können damit direkt Einfluss auf den Kohlenhydrat- und Energiestoffwechsel sowie die Regulation der Nahrungsaufnahme nehmen. Über eine PPARα-abhängige Induktion von CAR im Rahmen der Fastenadaption könnten die CAR-Zielgene UDP-Glucuronyltransferase 1A1 und Sulfotransferase N beispielsweise verstärkt Schilddrüsenhormone abbauen und in der Folge den Grundumsatz senken. Der in dieser Arbeit erstmals beschriebene Mechanismus ist dafür von zentraler Bedeutung. / Fatty acid metabolism is tightly regulated. Thus the activity and expression level of specific enzymes involved in fatty acid turnover are controlling fatty acid catabolism. The nuclear receptor peroxisome proliferator activated receptor α (PPARα) acts as the key regulator of these pathways. PPARα is activated by intracellular free fatty acids and promotes the fatty acid transport and break down, as well as gluconeogenesis and ketogenesis, via induction of target genes. An increase in free fatty acids as seen in fasting and diabetes activates PPARα. Under these conditions, an elevated expression of another nuclear receptor, the constitutive androstane receptor (CAR) and its target genes, mainly enzymes catalysing biotransformation such as cytochrome P450 2B (CYP2B1), was also observed. It is therefore likely that as yet unidentified modes of interaction between PPARα and CAR signalling exist. The object of the present work was to discover these underlying mechanisms utilising an in vitro model, the PPARα-agonist induced increase of the phenobarbital (PB)-dependent induction of the CAR target gene CYP2B1. Furthermore, an in vivo study would serve to demonstrate the physiological relevance of a PPARα-agonist induced modulation of the CYP2B activity. The synthetic PPARα agonists under investigation significantly enhanced the PB-dependent mRNA and protein expression as well as activity of CYP2B in primary rat hepatocytes. Without prior treatment with PB, PPARα agonists did not induce CYP2B activity. In the presence of PB, PPARα agonists increased the CYP2B activity dose-dependently. Luciferase reporter gene assays showed that the PB-dependent induction of the CY2B1 promoter relied on a distal PBREM (PB-responsive enhancer module), a well-known CAR binding site. PPARα agonists enhanced this PB- and PBREM-dependent reporter gene transcription and induced the upregulation of CAR mRNA and CAR protein expression. The PPARα agonists also activated the transcription of a reporter gene controlled by up to 4.4 kb upstream of the putative CAR-transcription start site. A potential peroxisome proliferator activated receptor responsive element (PPRE), essential for the initiation of transcription by PPARα agonists, could be identified between -942 bp to -930 bp upstream of the transcription start site using CAR promoter deletion constructs. In subsequent band shift experiments, enhanced nuclear protein accumulation with this specific promoter region was observed. In contrast to unlabelled wild-type CAR reporter gene vector, an excess of unlabelled CAR reporter gene vector with PPRE deletion did not compete with the binding of nuclear protein. Furthermore, this PPRE could be amplified with specific primers after chromatin immunoprecipitation with a PPARα antibody. Treatment of rats with a PPARα agonist resulted in a significant induction of CAR mRNA expression and significantly increased PB-dependent CYP2B activity. A physiological relevance of this newly-discovered mechanism is confirmed by the observation that PPARα-deficient mice, unlike wild-type mice, do not respond to fasting with an increase of CAR mRNA expression. The results of these experiments suggest that activated PPARα binds to the PPRE of the CAR promoter to initiate transcription of the CAR gene. CAR therefore could be regarded as a PPARα target gene, which implicates that PPARα- and CAR-signalling are directly linked through binding of PPARα to the CAR promoter. For subsequent enhanced induction of CAR target genes, activation of CAR, for instance using PB, is required. In vivo studies with PPARα agonists in rats support the relevance of the PPARα-dependent CAR expression. CAR target genes code for enzymes that metabolise not only a wide range of xenobiotics, but also thyroid hormones and glucocorticoids. CAR target genes could therefore directly interfere with carbohydrate and energy metabolism, as well as with food intake. PPARα-dependent induction of CAR upon fasting could lead to an increased expression of the CAR target genes UDP-glucuronyl transferase 1A1 and sulfotransferase N, resulting in an enhanced degradation of thyroid hormones, and decreased resting energy expenditure. The findings of this present study are of primary importance since it is the first time that this mechanism has been described.

Nuclear receptors are ligand activated transcription factors, where upon binding with small molecule ligands, these proteins are involved in the regulation of gene expression. To date there are approximately 48 human nuclear receptors known, involved in multiple biological and cellular processes, ranging from differentiation to maintenance of homeostasis. Due to their critical role in transcriptional regulation, these receptors are implicated in several diseases. Currently, 13% of prescribed drugs in the market are NR ligands for diseases such as cancer, diabetes and osteoporosis. In addition to drug discovery, the mechanism of function, mobility and trafficking of these receptors is poorly understood. Gaining insight into the relationship between the function and /or dysfunction of these receptors and their mobility will aid in a better understanding of the role of these receptors. The green fluorescent protein (GFP) has revolutionized molecular biology by providing the ability to monitor protein function and structure via fluorescence. The fluorescence contribution from this biological marker is the chromophore, formed from the polypeptide backbone of three amino acid residues, buried inside 11-stranded â-barrel protein. Synthesis of GFP derivatives of is based on the structure of the arylmethyleneimidazolidinone (AMI), creating a molecule that is only weakly fluorescent. Characterizing these AMI derivatives for other proteins can provide a powerful visualization tool for analysis of protein function and structure. This development could provide a very powerful method for protein analysis in vitro and in vivo. Development of such fluorescent ligands will prove beneficial for the nuclear receptors. In this work, libraries of AMIs derviatives were synthesized by manipulating various R groups around the core structure, and tested for their ability to serve as nuclear receptor ligands with the ability to fluoresce upon binding. The fluorogens are developed for steroidal and non-steroidal receptors, two general classes of nuclear receptors. Specific AMIs were designed and developed for steroid receptor estrogen receptor á (ERá). These ligands are showed to activate the receptor with an EC50 of value 3 ìM and the 10-fold activation with AMI 1 and AMI 2 in comparison to the 21-fold activation observed with natural ERá ligand, 17â-estradiol. These novel ligands were not able to display the fluorescence upon binding the receptor. However, fluorescence localized in nucleus was observed in case of another AMI derivative, AMI 10, which does not activate the receptor. Such ligands open new avenues for developing fluorescent probes for ERá that do not involve fluorescent conjugates attached to a known ERá ligand core. AMIs were also characterized for non-steroidal receptors,specifically the pregnane x receptor (PXR) and retinoic acid receptor á (RARá). To date, fluorogens which turn fluorescence upon binding and activate the receptor have not been developed for these receptors. With respect to PXR, several AMI derivatives were discovered to bind and activate this receptor with a fold-activation better than the known agonist, rifampicin. The best characterized AMI derivative, AMI 4, activates the receptor with an EC50 of value 6.3 ìM and the 154-fold activation in comparison to the 90-fold activation and an EC50 value of 1.3 ìM seen with rifamipicin. This ligand is not only able to activate PXR but also displays fluorescence upon binding to the receptor. The fluroscence pattern was observed around the nucleus. Besides AMI 4, 16 other AMI derivatives are identified that activate PXR with different activation profiles. Thus, a novel class of PXR ligands with fluorescence ability has been developed. The AMI derivatives able to bind and activate RAR, also displayed activation profiles that were comparable to the wild-type ligand, all trans retinoic acid. These ligands activated the receptor with an EC50 value of 220 nM with AMI 109 in comparison to an EC50 value of 0.8 nM with the natural ligand for RARá. When these ligands were tested for fluorescence in yeast, the yeast were able to fluoresce only in the presence of the receptor and the AMI derivative, indicating that these agonists also have the ability to fluoresce.

Small molecule dependent molecular switches that control gene expression are important tool in understanding biological cellular processes and for regulating gene therapy. Nuclear receptors are ligand activated transcription factors that have been engineered to selectively respond to synthetic ligands and used as regulators of gene expression. In this work the retinoid X receptor (RXR), has been used to develop an inducible molecular switch with a near drug like compound LG335. Three RXR variants (Q275C; I310M; F313I), (I268A; I310A; F313A; L436F), (I268V; A272V; I310M; F313S; L436M) were created via site-directed mutagenesis and a structure based approach, such that they preferentially bind to the synthetic ligand LG335 and not its natural ligand, 9-cis retinoic acid. These variants show reverse ligand specificity as designed and have an EC50 for LG335 of 80 nM, 30 nM, 180 nM, respectively. The ligand binding domains of the RXR variants were fused to a yeast transcription factor Gal4 DNA binding domain. This modified chimeric fusion protein showed reverse response element specificity as designed and recognized the Gal4 response element instead of the RXR response element. The modified RXR protein did not heterodimerize with wild type RXR or with other nuclear receptor such as retinoic acid receptor. These RXR-based molecular switches were tested in retroviral vectors using firefly luciferase and green fluorescence protein and they maintain their inducible behavior with LG335. These experiments demonstrate the orthogonality of RXR variants and their possible use in regulating gene therapy.

Proper embryonic development requires precise genetic regulation of cell growth and differentiation. Organogenesis, the origin and formation of internal organs, must be exquisitely choreographed to ensure correct temporal and spatial patterning of functional organs within the developing organism. The liver is a vital organ responsible for hundreds of essential metabolic functions, but the intricate pathways controlling organ specification, differentiation, and positioning have not been fully elucidated. Uncovering the molecular mechanisms involved in hepatogenesis will enhance our understanding of normal liver development as well as inform the design of therapeutics to combat liver disease. Nuclear receptors are evolutionarily recent signal transducers that occupy a special niche in gene regulation, acting as direct connections between a ligand and its downstream transcriptional target. Nuclear receptor signaling governs many physiological processes, however its impact on liver development is not well understood.

No description available.

The neuron-derived orphan receptor 1 (NOR1) belongs to the NR4A nuclear receptor subfamily. As an immediate early response gene, NOR1 is rapidly induced by a broad spectrum of physiological and pathological signals. Functional studies demonstrate NOR1 as a constitutively active ligand-independent nuclear receptor whose transcriptional activity is dependent on both expression level and posttranslational modifications. To date, an increasing number of studies have demonstrated a pivotal role of NOR1 in the transcriptional control of metabolism and the development of cardiovascular diseases. In this dissertation, we demonstrate NOR1 expression in endothelial cells and sub-endothelial cells of human atherosclerotic lesions. In response to inflammatory stimuli, NOR1 expression is rapidly induced in endothelial cells through an NF-κB-dependent signaling pathway. Functional studies reveal that NOR1 increases monocyte adhesion by inducing the expression of adhesion molecules VCAM-1 and ICAM-1 in endothelial cells. Transient transfection and chromatin immunoprecipitation assays identify VCAM-1 as a bona fide NOR1 target gene in endothelial cells. Finally, we demonstrate that NOR1-deficiency reduces hypercholesterolemia-induced atherosclerosis formation in apoE-/- mice by decreasing the macrophage content of the lesion. In smooth muscle cells (SMC), NOR1 was previously established as a cAMP response element binding protein (CREB) target gene in response to platelet-derived growth factor (PDGF) stimulation. CREB phosphorylation and subsequent binding of phosphorylated CREB to the NOR1 promoter play a critical role in inducing NOR1 expression. In this dissertation, we further demonstrate that histone deacetylase (HDAC) inhibition potentiates and sustains PDGF-induced NOR1 mRNA and protein expression in SMC. This augmented NOR1 expression is associated with increased phosphorylation of CREB, recruitment of phosphorylated CREB to the NOR1 promoter, and trans-activation of the NOR1 promoter. Additionally, HDAC inhibition also increases NOR1 protein half-life in SMC. Collectively, these findings identify a novel pathway in endothelial cells underlying monocyte adhesion and expand our knowledge of the epigenetic mechanisms orchestrating NOR1 expression in SMC. Finally, we establish a previously unrecognized atherogenic role of NOR1 in positively regulating monocyte recruitment to the vascular wall.

Submitted by Claudia Rocha (claudia.rocha@udesc.br) on 2018-03-16T13:45:25Z No. of bitstreams: 1 PGCA17MA219.pdf: 853811 bytes, checksum: 5ed849be56df67865d9463e92b006618 (MD5) / Made available in DSpace on 2018-03-16T13:45:25Z (GMT). No. of bitstreams: 1 PGCA17MA219.pdf: 853811 bytes, checksum: 5ed849be56df67865d9463e92b006618 (MD5) Previous issue date: 2017-02-22 / Capes / The search for optimization of production systems with animals leads to besides the animal fator, and show us that the micro components are the ones which sustain the production factores. On this way the nutrigenomic animal gains more importance and prominent in the search forresourse efficiency. Thereby the aim of this work was to analyse the effects of peroxisome proliferator activated gamma receptors (PPARγ) in the transcription of lipogenic genes and its response to conjugated linoleic acid (mixture of isomers trans-10, cis12 and cis-9, trans-11) through a specific chemical agonist (TZD, thiazolinedione). 1) Control: growing medium, 400μl; 2) TZD: 40ml (10μMol/Lt); 3) CLA (50% of CLA trans10, cis-12 and 50% of CLA cis-9, trans-11): 30ml (315μMol/Lt) and 4) TZD+CLA: 40ml TZD (10μMol/Lt) + 30ml (315μMol/Lt). It was extracted the RNA, synthesized the complementary DNA (cDNA), and carried out the polimerase chain reaction in Real Time (PCR – Real Time), measured the genetic expression of isoform PIII of acetyl-CoA-carboxylase alpha (ACCα), fatty acid synthase (FASN), peroxisome proliferator activated gamma receptors (PPARγ), sterol regulatory elemento-binding protein 1 (SREBP1), cleavage activation protein of SREBP1 (SCAP), stearoyl-CoA-desaturase (SCD), insulin induced gene 1(INSIG1), insulin induced gene 2(INSIG2). Compared to control, the treatment TZD increased the genes expression being SREBP1(1010%), INSIG1 (789%), INSIG2 (849%), FASN (7831%), ACCα (8753%), SCD (6272%) and PPARγ (620%). Compared to the TZD+CLA treatment, the TZD treatment increased the expression of the genes SREBP1 (237%), ACCα (1729%), INSIG1 (7142%) and PPARγ (2480%). Compared to CLA treatment, TZD increased the expression of FASN (275%), SCAP (916%), SCD (206%) and INSIG2 (1700%). It was concluded that the use of chemical agonist TZD in explants of the mammary gland of ewes, grown in vitro has acted to induce a greater expression of PPARγ and CLA reduces the genes expression FASN, ACCα, SCD and SCAP. In the TZD+CLA treatment, the TZD does not exceed the capacity of reducing CLA gene expression for the PPARγ, FASN, SCD, SCAP, INSIG1 and INSIG2 / A busca pela otimização dos sistemas produtivos com animais conduz para além do fator animal, e nos mostram que os componentes “micro” são que sustentam os fatores de produção. Deste modo a nutrigenômica animal ganha cada vez mais importância e destaque na busca pela eficiência de recursos. Com isso, o presente trabalho visou analisar o efeito dos receptores ativados por proliferadores de peroxissomo gama (PPARγ) na transcrição de genes lipogênicos e sua resposta ao ácido linoleico conjugado (CLA, com os isômeros trans-10, cis-12 e cis-9, trans-11), através de um agonista químico específico (TZD, thiazolinediona). No experimento foram realizados cultivos de explantes de glândula mamária de ovelhas lactantes, submetidos aos seguintes tratamentos: 1) Controle: meio de cultivo, 400μl; 2) TZD: 40mL (10 μMol/Lt); 3) CLA: (50% de trans-10, cis-12 e 50% de cis-9, trans-11): 30mL (315 μMol/Lt) e; 4) TZD + CLA: 40mL TZD (10 μMol/Lt) + 30mL (315 μMol/Lt). Foi extraído o RNA, sintetizado o DNA complementar (cDNA) e realizado a reação da cadeia da polimerase em tempo real (PCR Real Time) e medida a expressão gênica da isoforma PIII da acetil-CoA-carboxilase alfa (ACCα), ácido graxo sintase (FASN), receptores ativados por proliferadores de peroxissomo gama (PPARγ), proteína de ligação ao elemento de resposta a esterol 1 (SREBP1), proteína de ativação de clivagem da SREBP1 (SCAP), estearoil-CoA-dessaturase (SCD), gene-1 induzido pela insulina (INSIG1), gene-2 induzido pela insulina (INSIG2). Comparado ao Controle, o TZD aumentou a expressão dos genes, sendo SREBP1 (1.010%), INSIG1 (789%), INSIG2 (849%), FASN (7831%), ACCα (8753%), SCD (6272%) e PPARγ (620%). Comparado ao tratamento TZD+CLA o TZD, aumentou a expressão dos genes SREBP1 (237%), ACCα (1729%), INSIG1 (7142%) e PPARγ (2480%). Em comparação ao tratamento CLA, o TZD aumentou a expressão da FASN (275%), SCAP (916%), SCD (206%) e INSIG2 (1700%). Conclui-se que o uso do agonista químico TZD em explantes da glândula mamária de ovelhas lactantes aumenta a expressão do PPARγ e o CLA reduz a expressão gênica da FASN, ACCα, SCD e SCAP. No tratamento TZD+CLA, o TZD não supera a capacidade de redução da expressão gênica do CLA para os genes PPARγ, FASN, SCD, SCAP, INSIG1 e INSIG2

L'acide rétinoïque (AR) joue un rôle important dans plusieurs processus cellulaires à travers la régulation de la différentiation cellulaire, de la prolifération et de l'apoptose. Ces propriétés sont à la base de l'utilisation de l'AR dans le traitement de plusieurs cancers dont la leucémie aiguë promyélocytaire. Décrypter comment l'AR contrôle l'expression de gènes spécifiques est un défi permanent pour l'étude des cancers. Les effets de l'AR sont médiés in vivo principalement par les récepteurs à l'acide rétinoïque (RARs). Il a été récemment démontré que la phosphorylation des RARs par différentes kinases est une étape nécessaire dans la régulation de leurs fonctions. Dans ce contexte, ma thèse a porté sur l’étude des mécanismes moléculaires de la régulation par phosphorylation des RARs. Nous nous sommes intéressés en particulier à deux aspects : l’effet de la phosphorylation sur le domaine de liaison au ligand (LBD) et sur le domaine N-terminal (NTD). Dans le cas du LBD, la phosphorylation induit la fixation de la Cycline H qui est une sous-unité du facteur de transcription TFIIH, alors que la phosphorylation du NTD induit une diminution d’affinité de liaison à la Vinexine beta qui est un co-répresseur. Nous avons étudié les effets de la phosphorylation par des simulations de dynamique moléculaire. Cette technique permet de caractériser la dynamique structurale et de quantifier les interactions qui stabilisent les états phosphorylés et non phosphorylés. Ce projet a permis de définir les bases moléculaires de la communication entre le RA et les cascades de phosphorylation et d’obtenir des informations originales sur des mécanismes régulateurs d’une grande importance. / Retinoic Acid (RA) plays a critical role in many cellular processus through regulatory effects on cellular differentiation, proliferation and apoptosis. This proprety is at the basis of RA therapy in the treatment of several diseases and cancers such as Acute Promyelocytic Leukemia. Deciphering how RA controls the expression of specific subsets of genes is therefore a permanent challenge in oncology. The effects of RA are mediated in vivo by the retinoic acid receptor (RAR), which consistsof three subtypes. A new concept has recently emerged according to which phosphorylation of RARs by different kinases is a necessary step in the regulation of their function. In this context, the specific aim of this thesis was the elucidation of the molecular mechanisms of the regulation of RAR mediated by phosphorylation. In particular, we focused on two aspects, the effects of phosphorylation of the ligand binding domain (LBD) and the effects on the N-terminal domain (NTD). In the case of the LBD, phosphorylation enhanced binding to cyclin H, a component of the TFIIH transcription factor, while phosphorylation of the NTD decreased binding to vinexinB, a corepressor protein. We used molecular dynamics simulations to characterize the structural dynamics of these proteins in both phosphorylated and unphosphorylated states and to quantify theirinteractions. From this project, we were able to define the molecular basis of the communication between RA-induced phosphorylation cascades and regulatory mechanisms of high importance.

Os receptores nucleares são de suma importância para os processos de sinalização intercelular nos eucariotos, uma vez que possuem a capacidade de convergir diferentes sinais internos e externos na regulação de programas genéticos. Estas proteínas funcionam, na sua maioria, como fatores de transcrição ativados por ligantes, sendo a via de comunicação direta entre as moléculas de sinalização e a resposta transcricional eliciada pelas mesmas. A programação genética, estabilizada ou modificada pelos receptores, afeta virtualmente todos os aspectos da vida dos organismos multicelulares, tais como a embriogênese, a homeostase, a reprodução, o crescimento e a morte celular. A regulação transcricional e a seletividade promovida por estas proteínas têm fomentado intensas pesquisas, as quais estão decifrando a complexa rede de eventos moleculares que relatam sua forma de ação. Será um desafio para o futuro o conhecimento completo das regras moleculares que definem sua maneira de promover o controle espacial e temporal da expressão gênica. Estas informações prometem trazer detalhes cruciais para o desenvolvimento de drogas mais eficientes e de grande valor terapêutico. Neste contexto, o principal objetivo dos estudos aqui apresentados foi o de aumentar o conhecimento sobre o comportamento e estrutura do receptor nuclear humano dos hormônios tireoidianos, isoforma β1 (hTRβ1), e do receptor nuclear humano do ácido retinóico 9-cis, isoforma ? (hRXRα). Para tal, aplicou-se a técnica de espalhamento de raios X a baixos ângulos para determinar-se, em solução, o envelope destes receptores contendo os domínios de ligação ao DNA e ao ligante. Paralelamente, investiu-se em diversas tentativas de cristalização dos mesmos. Os resultados obtidos permitiram a determinação da localização espacial dos diferentes domínios e as organizações quaternárias dos homodímeros e homotetrâmeros. Conseqüentemente, foram propostos os primeiros modelos estruturais de receptores nucleares contendo os domínios de ligação ao DNA e ao ligante. O comportamento oligomérico, em solução, do hTRβ1 também foi analisado qualitativamente. Verificou-se que a formação do homodímero e do homotetrâmero é influenciada pela presença do hormônio T3, pela concentração protéica, pelos domínios presentes e por mutações específicas. Estes estudos geraram a hipótese de que o receptor nuclear hTRβ1 é capaz de se autoreprimir. Até então, dentro da superfamília dos receptores nucleares, esta capacidade de autorepressão somente havia sido descrita para o receptor hRXRα. Por fim, cristalizou-se o domínio LBD do receptor hTRβ1 com os ligantes T3, Triac e GC-1. O objetivo foi o de determinar estruturas cristalográficas importantes para o futuro desenvolvimento de tiromiméticos de ação isoforma-seletiva. / In eukaryotes, nuclear receptors are of major importance for intercellular signaling because they join different intra and extracellular signals during regulation of genetic programs. The great majority of these proteins function as ligand activated transcription factors providing a direct link between signaling molecules and the transcriptional responses elicited by them. The genetic programs that these receptors establish or modify affect virtually all aspects of the multicellular organisms? life, such as embryogenesis, homeostasis, reproduction, cell growth, and death. Their gene-regulatory power and selectivity has prompted intense research which is now starting to decipher the complex network of molecular events involved in transcription regulation. The future challenge will be to uncover the molecular rules that define spatial and temporal control of gene expression. Such knowledge would be essential to the development of more efficient drugs with better therapeutic values. Therefore, the main purpose in this study was to extend the understanding on the behavior and the structure of human thyroid receptor, isoform ?1 (hTRβ1), and human retinoic acid X receptor, isoform ? (hRXRα). It was applied the small angle X-ray scattering technique to determine, in solution, the envelop of both receptors containing DNA and ligand binding domains. Beside this, several crystallization conditions were tried for both receptors. The results made possible to define the spatial localization of the domains and the quaternary structure of the homodimers and homotetramers. Consequently, we were able to propose the first structural models for nuclear receptors containing the DNA and ligand binding domains. The oligomeric behavior of the hTRβ1, in solution, was also analyzed qualitatively. We verified that it was influenced by the presence of T3 hormone, the protein concentration, the presence of both DNA and ligand binding domains, and by specific mutations. Based on these results, we were able to hypothesize that the hTRβ1 has the capacity of autorepression. Up to now, only the hRXRα, in the whole nuclear receptor superfamily, had been described to behave similarly. Finally, we crystallized the ligand binding domain of the hTRβ1 in the presence of the ligands T3, Triac, and GC-1. The objective was to solve crystallographic structures essential for the future development of tiromimetics with isoform-selective action.

Orientador: Munir Salomão Skaf / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Quimica / Made available in DSpace on 2018-08-14T02:11:37Z (GMT). No. of bitstreams: 1 Souza_PauloCesarTellesde_M.pdf: 12351000 bytes, checksum: dc51e5bda58323fa5ce35779e31e9302 (MD5) Previous issue date: 2009 / Resumo: Os Receptores Nucleares (NRs) são proteínas que têm a função de regular a transcrição de genes através da associação com hormônios. Os NRs são formados por até quatro domínios, sendo o mais importante, o Domínio de Ligação com Ligante (LBD). O Receptor do Hormônio Tireoideano (TR) é um NR responsável por diversas funções no corpo, como controle da frequência cardíaca e do metabolismo de lipídios. Existem dois grupos de isoformas do TR: a e b. As diferenças entre eles são importantes para o desenho de novos fármacos seletivos, a serem utilizados no tratamento de disfunções tireoideanas como a Síndrome de Resistência ao Hormônio Tireoideano (RTH), causada por mutações no TRb. Existem poucos estudos que mostram como mudanças estruturais e dinâmicas decorrentes de mutações podem levar a perdas funcionais. Neste trabalho, foram estudados os efeitos de mutações na estrutura do LBD do TRb, através de simulações de dinâmica molecular. Em uma primeira etapa, foram escolhidos cinco mutantes para um estudo mais detalhado. Verificou-se que duas de três mutações estudadas no resíduo I280 provocam modificações estruturais na hélice H12, que podem explicar a perda de interação com correguladores, observada em experimentos. Além disso, verificou-se que essas e outras mudanças induzem a entrada de água no sítio de ligação. Já os mutantes L428R e R429Q apresentaram diferenças importantes com relação à estrutura nativa na região de dimerização, na hélice H12 (que interage com correguladores) e no grampo b (envolvido com a dissociação de hormônios). Análises mais globais de simulações de 40 mutantes, mostraram que, em grande parte, as mutações promovem instabilidade do LBD, perda de interação com hormônio, e entrada de água no sítio de ligação, inclusive em regiões hidrofóbicas. Estes resultados podem explicar a perda de afinidade pelo hormônio, mesmo em mutações longe do sítio de ligação / Abstract: Nuclear Receptors (NRs) are proteins that have role of regulating the transcription of genes through the association with hormones. The NRs are formed by up to four domains, being the Ligant Binding Domain (LBD) the most important one. Thyroid hormone receptor (TR) is responsible for several functions in the body, such as control of the heart rate and of the metabolism of lipids. There are two groups of the TR isoforms: a and b. Differences between them are important for the design of new selective drugs to be used in the treatment of thyroid disorders such as resistance to thyroid hormone syndrome (RTH), caused by mutations in TRb. There are just a few studies that show how structural and dynamical changes caused by mutations may lead to functional loss. In this work we studied the effects of mutations in the structure of the TRb LBD by applying molecular dynamics technique. First, we have chosen five mutants for a more detailed investigation. We found that two of three studied mutations in residue I280 caused structural changes in helix H12, what can explain the loss of interaction with coregulators, recently seen in experiments. We also found that these and other changes induce the water entrance in the binding site. On the other hand, the L428R and R429Q mutants have shown important differences related to native structure in the dimerization region, helix H12 (which interacts with coregulators) and b-hairpin (involved in the dissociation of hormones). The results of global analysis carried out for 40 mutants showed that the mutations are greatly responsible for instability of LDB region, loss of interaction with hormone and water entrance even in hydrophobic regions. These results may explain the loss of affinity with the hormone, even when the mutated region is located far from the ligand binding site / Mestrado / Físico-Química / Mestre em Química